Skip to NavigationSkip to content

News

0
Roche has unveiled new Phase 1/2 data for its selective tyrosine kinase inhibitor entrectinib, demonstrating its ability to shrink recurrent or...
0
Gilead, Janssen and BMS accused of forging anticompetitive deal; Novartis buy Takeda's dry eye drug Xiidra for $5.3 billion; NHS England to pay for...
0
The FDA has announced its approval of Pfizer’s anticoagulant injection Fragmin (dalteparin sodium) for subcutaneous use as a treatment to reduce...
0
US Representative Alexandria Ocasio-Cortez tore into Gilead CEO Daniel O’Day on Thursday, over the firm’s nearly $2,000 price tag on PrEP drug,...

Features

“If you are looking to make a difference in how business is done, perseverance and patience are crucial”